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Abstract: Sixteen longSAGE libraries from four different clinical stages of cervical intraepithelial neoplasia have enabled 
us to identify novel cell-surface biomarkers indicative of CIN stage. By comparing gene expression proﬁ  les of cervical 
tissue at early and advanced stages of CIN, several genes are identiﬁ  ed to be novel genetic markers. We present ﬁ  fty-six 
cell-surface gene products differentially expressed during progression of CIN. These cell surface proteins are being exam-
ined to establish their capacity for optical contrast agent binding. Contrast agent visualization will allow real-time assessment 
of the physiological state of the disease process bringing vast beneﬁ  t to cancer care. The data discussed in this publication 
have been submitted to NCBIs Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) and are accessible 
through GEO Series accession number GSE6252.
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Introduction
Clinical diagnosis of most cancers and their precursors is predominantly based on phenotypic markers 
such as appearance of cell nuclei. Classiﬁ  cation and staging of disease is determined by evaluation of 
gross structural features, such as extent of local tumour invasion and presence of disease in other organs. 
It is now established that cancer arises as a result of successive genetic changes altering cellular pro-
cesses including growth, angiogenesis, senescence, and apoptosis (Hanahan and Weinburg, 2000). 
Additionally, many cancers appear to have active inﬂ  ammation and wound healing mechanisms (Chang 
et al. 2004). Proteins taking part in these cellular mechanisms are often strong candidates for biomark-
ers and molecular targets.
Cervical cancer is usually the result of a human papillomavirus (HPV) infection which initiates 
neoplastic progression mainly through viral oncoproteins E6 and E7 within the cervical transforma-
tion zone at the squamous/columnar junction. The role of HPV to the pathogenesis of cervical cancer 
has been addressed in recent reviews (zur Hausen, 2002; Woodman et al. 2007). Many HPV types 
produce only productive lesions following infection and are not associated with human cancers. In 
such lesions, the expression of viral gene products is carefully regulated, with viral proteins being 
produced at deﬁ  ned times and at regulated levels as the infected cell migrates towards the epithelial 
surface. The events that lead to viral synthesis in the upper epithelial layers appear common to both 
the low- and high-risk HPV types. Virus-induced cancers most often arise at sites where productive 
infection cannot be suitably supported. Productive infection can be divided into distinct phases, with 
different viral proteins playing speciﬁ  c roles (Doorbar, 2006). Upon infection, normal cells gradually 
advance through stages of cervical intraepithelial neoplasia (CIN). Mild dysplasia (CINI) presents 
as only a subset of the low third of the epithelium appearing dysplastic, moderate dysplasia (CINII) 
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occurs where the dysplastic cells involve about 
one-half of the thickness of the epithelium of the 
cervix, and severe dysplasia (CINIII), or carci-
noma-in-situ, is described as the condition where 
the entire thickness of the epithelium is disordered 
but the abnormal cells have not yet spread below 
the surface. If carcinoma-in-situ is not treated, it 
will often grow into an invasive cervical cancer. 
High grade dysplasia is considered the most 
advanced dysplasia with atypical changes in many 
of the cells and a very abnormal growth pattern 
of the glands; some of the glands are branching 
or budding. More than 50% of the cells have large, 
spotted nuclei and are frequently dividing while 
the cellular cytoplasm is reduced and looks abnor-
mal. Cancer of the cervix was one of the most 
common causes of cancer death for American 
women, but between 1955 and 1992 the number 
of cervical cancer deaths in the United States 
dropped by 74% due to the introduction of the 
Pap test (Papanicolaou and Traut, 1943). Death 
rates from cervical cancer continue to decline by 
nearly 4% per year. Even so, the American Can-
cer Society reports that in 2006, about 3,700 of 
the 9,710 women diagnosed with cervical cancer 
in the United States have died from this disease.
HPV infection causes changes in expression 
levels of a wide variety of genes (Yim and Park, 
2006). These differences in gene expression 
between pre-invasive neoplastic and non-neoplastic 
tissue give clues to the molecular basis of cancer. 
Early detection of cervical cancer based on molec-
ular characterization would be clinically advanta-
geous; risk of neoplastic lesion progression could 
be predicted and response to therapy could be 
monitored in real time at a molecular level. To 
monitor molecular characterisation of cancer it 
follows that the ability to optically image in real-
time the molecular features of cancer in vivo is 
critical (González et al. 1999; Rajadhyaksha et al. 
1999; White et al. 1999; Huzaira et al. 2001; 
Langley et al. 2001; Selkin et al. 2001; Collier et al. 
2002) and requires safe, molecular-speciﬁ  c con-
trast agents whose images can be monitored rapidly 
and non-invasively during their uptake and distri-
bution. The analysis presented here evaluates serial 
analysis of gene expression (SAGE) libraries to 
identify novel, cell-surface gene products. Upon 
mapping of highly differentially expressed SAGE 
tags to their corresponding genes, the gene prod-
ucts are candidates for antibody testing and optical 
contrast agent development.
Contrast Agents and Optical Imaging
Short of prevention, improved early stage cancer 
diagnosis would provide the greatest beneﬁ  t for 
cancer patients. Because proteins may regulate gene 
expression, ligand-binding properties, molecular 
structure and dynamics on a temporal basis, protein 
biomarkers have a signiﬁ  cant impact in cancer 
detection and therapy as therapies are becoming 
targeted to speciﬁ  c signal transduction and meta-
bolic pathways. For example, breast cancers respond 
to HERCEPTIN (trastuzumab) if the tumor over-
expresses Her-2/neu (Baselga et al. 2004; Ross et al. 
2004). In the same way, GLEEVEC (imatinib) is 
most effective against cancers carrying the bcr-Abl 
translocation (Druker, 2004) and targeted molecular 
cancer therapy is already used successfully for the 
eradication of acute leukaemia (Frater et al. 2003; 
Yee and Keating, 2003). These examples imply that 
it will be important to produce biomarkers for all 
stages of cancer. Reliable diagnostics such as DNA 
screening and immunocytochemical analysis of 
known cervical neoplasia biomarkers p16
INK4A and 
minichromosome maintenance (MCM) proteins are 
not implemented in vivo. Real-time biomarkers of 
the physiological state of the disease process or 
markers representative of treatment efﬁ  cacy will 
bring immeasurable beneﬁ  t to cancer care in terms 
of individualized agent selection and dosing. Fur-
thermore, series of agents could be tested to deter-
mine empirically the localization of cancer and/or 
the most effective therapy.
Routine clinical cancer detection employs non-
speciﬁ  c contrast agents such as acetic acid which 
enhance the nuclear backscattering but are limited 
by small signal magnitude. The ﬁ  eld of molecular 
imaging is rapidly developing imaging agents with 
high afﬁ  nity and speciﬁ  city for targeted biomark-
ers. These new agents allow for the possibility of 
disease detection earlier than is currently feasible 
(Weissleder, 2001; Jaffer and Weissleder, 2005). 
For example, cancer metastases missed by conven-
tional anatomically based imaging methods may 
be detected in patients by molecular imaging 
(Harisinghani et al. 2003). Optical imaging of tis-
sue can be carried out non-invasively in real time, 
giving high spatial resolution (1 µm lateral reso-
lution). A number of optical techniques have been 
established including confocal microscopy (White 
et al. 1999; Collier et al. 2005), multispectral ﬂ  uo-
rescence imaging (Andersson-Engels et al. 1997; 
Ferris et al. 2001), reﬂ  ectance spectroscopy with 
polarised and unpolarised light (Sokolov et al. 449
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1999, 2002; Utzinger et al. 2001), multispectral 
reﬂ  ectance imaging with polarised and unpolarised 
light (Ferris et al. 2001; Gurjar et al. 2001), and 
ﬂ  uorescence spectroscopy (Gillenwater et al. 1998; 
Wagnières et al. 1998; Ramanujam, 2000; Sokolov 
et al. 2002). Together with emerging molecular 
tools (e.g. DNA screening, tissue proteomic and 
serum markers), biomarker imaging may soon be 
used for real-time screening, diagnosis, and detec-
tion of disease recurrence and progression (Rudin 
and Weissleder, 2003).
Contrast agents consist of a biomarker speciﬁ  c 
probe molecule, such as an antibody, conjugated 
to an optically suitable label. By topically applying 
molecular speciﬁ  c contrast agents to tissues, the 
scope of molecular changes that can be probed 
using optical imaging is signiﬁ  cantly enhanced. 
Presently, contrast agents based on metal nanopar-
ticles, organic ﬂ  uorescent dyes, and quantum dots 
coupled to monoclonal antibodies against cancer 
speciﬁ  c biomarkers are being developed (Sokolov 
et al. 2003; Rahman et al. 2005).
SAGE Libraries and Tag Mapping
The SAGE technique is capable of producing a 
molecular representation of cervical tissue based 
on expressed genes. SAGE is not dependent on 
pre-existing databases of expressed genes and so 
provides an independent view of gene expression 
proﬁ  les within the mRNA populations (Velculescu 
et al. 1997). SAGE library construction is well 
documented in the literature (Velculescu et al. 1995 
and 1997; Madden et al. 2000; Saha et al. 2002; 
Pleasance et al. 2003; Sander et al. 2005). Several 
recent gene expression proﬁ  les of in vitro HPV-
infected cultured keratinocytes and from cervical 
carcinoma clinical samples have proposed changes 
in gene expression induced by HPV and in early 
cervical carcinomas (Thomas et al. 2001; Ruutu 
et al. 2002; Duffy et al. 2003; Pérez-Plasencia et al. 
2005). Some studies have compared normal versus 
tumor-induced gene expression in cervical samples 
with the aim of identifying potential tumor mark-
ers of clinical value (Shim et al. 1998; Chen et al. 
2003).
To identify genes expressed at dissimilar levels 
in preinvasive neoplastic and non-neoplastic 
untyped cervical tissue, we analysed sixteen long-
SAGE libraries; 4 from normal cervical tissue 
samples, 3 of a mild dysplasia (CINI), 3 of moder-
ate dysplasia (CINII), and 6 of severe dysplasia 
(CINIII), or carcinoma-in-situ. The CIN tissues are 
positive for MUC16. Raw numbers of longSAGE 
tags generated and library names are given in Tables 
1 and 2. DiscoverySpace (Robertson et al. 2007), 
an in-house graphical software application backed 
by a relational database system designed to support 
SAGE gene expression analysis, was used to query 
data from over 25 publicly available data sources, 
as well as internal experimental results. Using 
DiscoverySpace, selected SAGE tag sequences 
were mapped to counterpart RefSeq (Pruitt et al. 
2000, 2005) genes and conﬁ  rmed using SAGE tag 
co-ordinates to establish gene identity through 
Ensembl (Hubbard et al. 2007; homo_sapiens_
core_41_36c). Genes were manually curated 
(EntrezGene) to ascertain gene identity and gene 
product localisation. These cervical longSAGE 
libraries were created from the epithelium of cervi-
cal biopsy samples collected just prior to LEEP 
(Loop Electrosurgical Excision Procedure). Tissue 
samples were placed into RNAIater and frozen at 
−80 °C within 10 minutes of being excised from 
the patient. These longSAGE libraries (Shadeo 
et al. 2007) have been submitted to the NCBI Gene 
Expression Omnibus (GEO) repository.
Any protein differentially expressed in cancer 
tissue, compared to normal tissue, or any protein 
known to be involved in cancer development, has 
potential as a candidate cancer biomarker. Genes 
presenting properties which identify them as likely 
targets for cancer diagnosis or prognosis must be 
separated from thousands of other genes which also 
may also possess clinical potential. Hundreds of 
potential candidates must be set aside in favour of 
gene products which offer the most promising 
characteristics. We focus on genes encoding mem-
brane associated proteins because membrane-bound 
proteins are most likely to be accessible to topical 
application of contrast agents and have a rapid time 
frame for contrast agent visualization. Genes 
expressing the greatest number of tags combined 
with high levels of differential expression between 
dysplastic and normal tissue are the most likely to 
be observed by contrast agents in vivo.
For optical imaging of tumors by topical appli-
cation in vivo of contrast agents to be of practical 
use, a large number of contrast agent receptors are 
required. One of the standard methods to detect 
candidate biomarkers is to identify genes with 
amplified expression in cancer and/or normal 
tissues. We compared transcription proﬁ  les and 
retained the most highly expressed membrane-bound 450
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gene products whose differential expression level 
is greater than two-fold. Many cell-surface proteins 
can potentially be developed as targets for optical 
contrast agents. Using longSAGE, we have also 
identiﬁ  ed the most highly differentially expressed 
transcripts between disease and normal tissue. 
Table 1 speciﬁ  es those genes (with cell-surface 
gene products) up-regulated in the CINI and CINIII 
stages of dysplasia and Table 2 lists genes up-
regulated in normal tissue. Short descriptions of 
these protein biomarkers are given in the appendix 
and annotations of protein structural information, 
if available, are included. Given that CINII is dif-
ﬁ  cult to determine clinically, it was not included 
in these comparisons. Contrast agent visualization 
of the epidermal growth factor receptor (EGFR) 
using an anti-EGFR monoclonal antibody has 
already been successful (Rahman et al. 2005). 
More of these markers should prove amenable to 
contrast agent development and topical formula-
tions consisting of a range of contrast agents could 
help adjust to individual patient differences in gene 
expression.
Cervical Intraepithelial Neoplasia 
Stage Biomarkers
It is possible to evaluate a marker for presence or 
absence, but to correlate a marker or array of mark-
ers to changes in cellular localization relative to 
other markers is probably the most interesting and 
beneﬁ  cial in terms of dysplasia progression, envi-
ronment, therapy selection, and follow-up. The 
known function of these genes grants some insight 
into the biology of cervical neoplasia. For instance, 
several of these cell surface markers are involved 
in transport and/or signaling. MUCX and CD74, 
upregulated in CINI and CINIII, have signaling 
gene products known to be associated with carci-
nomas. CD74 is also known to be a high afﬁ  nity 
binding protein for macrophage migration-inhibi-
tory factor (MIF) which is implicated in tumor cell 
growth and angiogenesis. TSPAN1, upregulated 
in CINIII almost 10-fold, also plays a role in cell 
motility and growth. See Appendix for gene-
speciﬁ  c references.
Our analysis of cervical cancer longSAGE 
expression proﬁ  les direct attention to some genes 
with relatively equal distribution in CINI and 
CINIII, such as PIGR. Another marker, ANPEP, is 
present at signiﬁ  cantly different expression levels 
in CINI and CINIII. This knowledge expands the 
possibilities for rapid visualization between normal 
and stages of dysplasia in vivo. As discussed earlier, 
these cell surface targets were found by identifying 
differentially expressed genes. More often than 
not, a highly expressed tag is not localised to the 
cell surface and, for these purposes, does not war-
rant further attention. However, a highly differen-
tially expressed gene whose gene product is not 
membrane-bound is sometimes found to be part of 
a mechanism which affects the cell surface and 
thereby the gene product becomes of potential use. 
TFF3 (trefoil factor 3), for instance, is up-regulated 
13-fold in CINIII and 27-fold in CINI. Members 
of the trefoil family are characterised by having at 
least one copy of the trefoil motif, a 40-amino acid 
domain that contains three conserved disulphides. 
They are stable, secretory proteins whose functions 
are not deﬁ  ned but may protect the mucosa from 
insults, stabilize the mucus layer and affect healing 
of the epithelium. VANGL1 (Van Gogh-like pro-
tein 1) is an integral membrane protein which is 
serine/threonine phosphorylated and translocated 
to cytoplasmic vesicles in response to TFF3 
stimulation (Kalabis et al. 2006). VANGL1 protein 
acts as a downstream effector of TFF3 signalling 
and regulates wound healing of intestinal epithe-
lium. TFF3 is commonly expressed in hepatocel-
lular carcinoma and its expression correlates with 
tumor grade (Khoury et al. 2005). TFF3 overex-
pression may be a critical process in mouse and 
human hepatocellular carcinogenesis (Okada et al. 
2005). The group of trefoil factor peptides (TFF1-
3) are part of the protective mechanism operating 
in the intestinal mucosa and play a fundamental 
role in epithelial protection, repair, and restitution 
(Vieten et al. 2005). TFF3 and the essential tumor 
angiogenesis regulator VEGF exert potent pro-
invasive activity through STAT3 signalling in 
human colorectal cancer cells (Rivat et al. 2005). 
That VANGL1 returned to cell membranes within 
45 minutes of TFF3 stimulation (Kalabis et al. 
2006) could explain the low VANGL1 tag counts, 
1–3 tags per library, observed in the longSAGE 
libraries.
Conclusions
Molecular speciﬁ  c contrast agents may provide the 
ability to directly image the cancer process; but 
biomarker discovery can be a lengthy process as 
candidate markers suitable for the task-at-hand 
must be identified from among thousands of 451
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Table 1. Highly expressed genes with membrane-bound gene products up-regulated in cervical dysplasia stages 
CINI and CINIII. Up-regulated gene expression, from normal, 2-fold.
Tag sequence Number 
of tags in 
disease 
libraries*
Number 
of tags in 
normal 
libraries
Gene Fold increase 
from normal
RefSeq 
accession 
number
CINIII
GACCCAAGATAAAAGAA 704 16 PIGR 22.4 NM_002644
ATCCCCCTGGGCATCGG 52 2 SLC39A3 13.2 NM_144564
ACTCAGACCAGGTCCCA 94 4 STRA6  11.4 NM_022369
ACACAGTATTCGCTCTT 44 2 ITR  11.2 NM_180989
TTACTTCCCCACCCCTA 84 4 FADS2 10.7 NM_004265
GGAACTGTGAAGAGGCA 230 12 TSPAN1   9.7 NM_005727
GCACCTGTCGCCCAGTG 36 2 ANPEP   9.2 NM_001150
CCTGATCTGCGGTGTCC 308 18 MUC16   8.7 NM_024690
CGTTTTCTGATAACTCA 68 4 PTP4A2   8.6 XM_001132367
CAAATAAATTATGCGAT 98 6 TMPRSS2   8.3 NM_005656
TGCTCCTACCCTGCTCT 2022 190 FCGBP   5.4 XM_001131379
GCAGTGCCACTCAAGAA 726 68 SRD5A2L   5.4 NM_024592
CCTGGGAAGTGTTGTGG 730 98 MUC1   3.8 NM_001044391
AATATTTATATTGTATG 1880 400 CEACAM5   2.4 NM_004363
GTTCACATTAGAATAAA 3424 762 CD74   2.3 NM_001025158
GGGCATCTCTTGTGTAC 1602 350 HLA-DRA   2.3 NM_019111
TGCTGCCTGTTGTTATG 826 192 BST2   2.2 NM_004335
CTGACCTGTGTTTCCTC 596 144 HLA-B   2.1 NM_005514
GCAGGGCCTCATCTCAC 1950 484 FXYD3   2.0 NM_005971
CINI
GCACCTGTCGCCCAGTG 42 2 ANPEP 36.5 NM_001150
ATGTTAATAAAATAGGC 66 4 GPC4 28.7 NM_001448
ATAAATGATTAGACTAC 32 2 CLIC6 27.8 NM_053277
GGCCAAGAACTTTCACT 28 2 C14orf101 24.3 NM_017799
GACCCAAGATAAAAGAA 262 16 PIGR 23.0 NM_002644
TAGGTCAGGACCTTGGC 26 2 PTP4A3 22.6 NM_032611
GTATATAACTCTTAAAG 24 2 LOC644410** 20.8 XM_001133198
CCAGCTGCCTGGAGGAG 22 2 MGC45438 19.1 NM_152459
ATAAAAATTAGGGGGAT 22 2 SLC30A1 19.1 NM_021194
TGAGCTACCCCAGAGTC 20 2 FER1L4 17.4 NR_001442
TACATCAGTAAAGAGTT 374 42 GAS1 12.5 NM_002048
CATCACGGATCAATAGA 330 64 IL1R1   7.2 NM_000877
CCTGGGAAGTGTTGTGG 334 98 MUC1   4.1 NM_001044391
TGCAGATTGCAGTTCTG 366 132 PROM1   3.9 NM_006017
CACTTCAAGGGCAGCCT 238 102 LY6E   3.3 NM_002346
GTTCACATTAGAATAAA 1660 762 CD74   3.1 NM_001025158
GGGCATCTCTTGTGTAC 734 350 HLA-DRA   3.0 NM_019111
TGCTCCTACCCTGCTCT 402 190 FCGBP   3.0 XM_001131379
CTGACCTGTGTTTCCTC 256 144 HLA-B   2.5 NM_005514
*GEO Series Accession Numbers GSE6252. 1,101,702 total longSAGE tags in four normal libraries, GEO Alias N3, N1, N2, N4; 2,165,777 
total longSAGE tags in six CINIII libraries, GEO Alias C1, C3, C2, C4,C5,C6; 785,642 total longSAGE tags in three CINI libraries, GEO Alias 
M1, M2, M3.
**Mapping unable to be conﬁ  rmed through ENSEMBL or BLAT.452
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Table 2. Highly expressed genes with membrane-bound gene products up-regulated in normal cervical tissue. 
Up-regulated gene expression, from CINI and/or CINIII, 2-fold.
Tag sequence Number 
of tags in 
disease 
libraries*
Number 
of tags in 
normal 
libraries
Gene Fold increase 
from disease 
state
RefSeq 
accession 
number
CINIII 
AGACTTGGCATACACAC 2 30 ACTR3 29.5 NM_005721
TAACTGGCCTTACGATG 6 54 DSG1 17.7 NM_001942
AGAGGGATGAGGCAACC 2 18 GJB2 17.7 NM_004004
AGTCCTGGAGGAGGAGA 2 18 PTPNS1 17.7 NM_001040022
GCTGACAGTCCCAAGTC 2 16 NIP 15.7 NM_144565
ACAGTCACCACGAGGAG 2 16 ODZ2 15.7 XM_047995
AGAGTTCTGTCACGGTC 8 62 UPK1A 15.2 NM_007000
CAGTATTTTAAATAATT 2 12 FLJ32028  11.8  NM_152680
ATAATCACCCTTCATCA 2 12 CACNA2D3  11.8  NM_018398
TGGTGGCTGCTTTTCCC 2 10 TMEM54   9.8  NM_033504
CCAGCGCCAACCAGTCA 272 482 LYPD3   3.5 NM_014400
GTTTCCAAAAAATGGTA 350 438 GJB2   2.5 NM_004004
GTGGAAGACGATAACCC 5664 7334 MAL   2.5  NM_002371
GCCCAGCATTCTCCACC 856 832 PSCA   1.9 NM_005672
CTTGATTCCCACGCTAC 236 230 QSCN6   1.9 NM_002826
GTTATTGAGGGCAAGAA 196 194 C3orf28   1.9 NM_014367
CINI
CAATCTTGCAGTGAAGA
TCAGAATGATTCTGGTG
6
22
226
346
TMPRSS11B 26.9
 11.2
NM_182502
AGAGTTCTGTCACGGTC 2 62 UPK1A 22.1 NM_007000
GCATAACAACTCCCCAA
TAATTTGCATTACTCTG
4
366
60
2036
EMP1 10.7
  4.0
NM_001423
GATCCAGATGCCTGAGG 4 74 LYNX1 13.2 NM_023946
CCAGCGCCAACCAGTCA 28 482 LYPD3 12.3 NM_014400
GATGAATCCGGGGTATG 4 68 TMEM45B 12.1 NM_138788
TATATTTTTAAATGTTC 2 30 TGFA 10.7 NM_003236
TAACCCCTCTCACCTGC 2 28 FGFR2 10.0 NM_022970
GGGACTAAAACTCACCC 2 28 MAL 10.0 NM_002371
GGAGGGAGCTGAGGGGT 2 28 EPHA1 10.0 NM_005232
GCCCAGCATTCTCCACC 82 832 PSCA   7.2 NM_005672
GTTATTGAGGGCAAGAA 30 194 C3orf28   4.6 NM_014367
GTTTCCAAAAAATGGTA 70 438 GJB2   4.5 NM_004004
GCTTCCTCGGTACCCTT 252 1590 RHCG   4.5  NM_016321
CCACAGGAGAATTCGGG 952 5624 PERP   4.2  NM_022121
GATATGTAAAAACTGTC 38 194 CLCA4   3.6  NM_012128
GCCTACCCGAGGAGAAG 132 616 TACSTD2   3.3  NM_002353
*GEO Series Accession Number GSE6252. 1,101,702 total longSAGE tags in four normal libraries, GEO Alias N3, N1, N2, N4; 2,165,777 
total longSAGE tags in six CINIII libraries, GEO Alias C1, C3, C2, C4,C5,C6; 785,642 total longSAGE tags in three CINI libraries, GEO Alias 
M1, M2, M3.453
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proteins. SAGE-identified biomarkers hold 
promise for recognition of the stages of neoplasia 
by proteomic patterns. Optical contrast agents 
bound to these membrane-bound protein biomark-
ers will serve as a complement to histopathology, 
thus allowing more effective determination of 
tumor borders and non-invasive observation of 
response to treatment at a molecular level. We 
present ﬁ  fty-six cell-surface gene products dif-
ferentially expressed during progression of cervi-
cal intraepithelial neoplasia. Differential gene 
expression of these biomarkers will allow indi-
vidualized selection of therapeutic combinations 
that best target the entire disease-protein system 
and advance understanding of carcinogenesis.
Acknowledgments
This work was supported by a grant from the 
National Institutes of Health (NIH/NCI 1R01-
CA103830-01) and by the British Columbia Can-
cer Foundation. MA Marra and SJM Jones are 
Scholars of the Michael Smith Foundation for 
Health Research and MA Marra is a Terry Fox 
Young Investigator of the National Cancer Institute 
of Canada. We also thank R Varhol, BCGSC, for 
tag mapping verﬁ  ciation.
References
Afar, D.E., Vivanco, I., Hubert, R.S. et al. 2001. Catalytic cleavage of the 
androgen-regulated TMPRSS2 protease results in its secretion by 
prostate and prostate cancer epithelia. Cancer Res., 61(4):1686–92.
Agnel, M., Vermat, T. and Culouscou, J.M. 1999. Identiﬁ  cation of three 
novel members of the calcium-dependent chloride channel (CaCC) 
family predominantly expressed in the digestive tract and trachea. 
FEBS. Lett., 455(3):295–301.
Andersson-Engels, S., Klinteberg, Ca., Svanber, K. et al. 1997. In vivo 
fluorescence imaging for tissue diagnostics. Phys. Med. Biol., 
42:815–24.
Arredondo, J., Chernyavsky, A.I., Jolkovsky, D.L. et al. 2006. SLURP-2: 
A novel cholinergic signaling peptide in human mucocutaneous 
epithelium. J. Cell. Physiol., 208(1):238–45.
Bagutti, C., Forro, G., Ferralli, J. et al. 2003. The intracellular domain of 
teneurin-2 has a nuclear function and represses zic-1-mediated trans-
cription. J. Cell. Sci., 116(Pt 14):2957–66.
Bamias, A., Chorti, M., Deliveliotis, C. et al. 2003. Prognostic signiﬁ  cance 
of CA 125, CD44, and epithelial membrane antigen in renal cell 
carcinoma. Urology, 62(2):368–73.
Bansal, G.S., Cox, H.C., Marsh, S. et al. 1997. Expression of keratinocyte 
growth factor and its receptor in human breast cancer. Br. J. Cancer, 
75(11):1567–74.
Bardelli, A., Saha, S., Sager, J.A. et al. 2003. PRL-3 expression in metas-
tatic cancers. Clin. Cancer Res., 9(15):5607–15.
Baselga, J., Gianni, L., Geyer, C. et al. 2004. Future options with trastuzu-
mab for primary systemic and adjuvant therapy. Semin. Oncol., 
31:51–7.
Becker-Herman, S., Arie, G., Medvedovsky, H. et al. 2005. CD74 Is a 
Member of the Regulated Intramembrane Proteolysis-processed 
Protein Family. Molecular Biology of the Cell, 16:5061–69.
Ben-Porath, I. and Benvenisty, N. 1996. Characterization of a 
tumor-associated gene, a member of a novel family of genes encoding 
membrane glycoproteins. Gene., 183(1–2):69–75.
Bernfield, M., Gotte, M., Park, P.W. et al. 1999. Functions of cell sur-
face heparan sulfate proteoglycans. Annu. Rev. Biochem., 
68:729–77.
Boch, J.A., Yoshida, Y., Koyama, Y. et al. 2003. Characterization of a 
cascade of protein interactions initiated at the IL-1 receptor. Biochem. 
Biophys. Res. Commun., 303(2):525–31.
Boehm, M.K. and Perkins, S.J. 2000. Structural Models for Carcinoembry-
onic Antigen and its Complex with the Single-Chain Fv Antibody 
Molecule Mfe23. FEBS. Lett., 475:11.
Bouillet, P., Sapin, V., Chazaud, C. et al. 1997. Developmental expression 
pattern of Stra6, a retinoic acid-responsive gene encoding a new type 
of membrane protein. Mech. Dev., 63(2):173–86.
Breslin, J.J., Mork, I., Smith, M.K. et al. 2003. Human coronavirus 229E: 
receptor binding domain and neutralization by soluble receptor at 37 
degrees C. J. Virol., 77(7):4435–8.
Cates, C.A., Michael, R.L., Stayrook, K.R. et al. 1996. Prenylation of 
oncogenic human PTP(CAAX) protein tyrosine phosphatases. Can-
cer Lett., 110(1–2):49–55.
Chang, H.Y., Sneddon, J.B., Alizadeh, A.A. et al. 2004. Gene expression 
signature of ﬁ  broblast serum response predicts human cancer pro-
gression: similarities between tumors and wounds. PloS. Biol., 
2(2):206–14.
Chen, Y., Miller, C., Mosher, R. et al. 2003. Identiﬁ  cation of cervical 
cancer markers by cDNA and tissue microarrays. Cancer Res., 
63:1927–35.
Collier, T., Lacy, A., Richards-Kortum, R. et al. 2002. Near real-time confo-
cal microscopy of amelanotic tissue: detection of dysplasia in ex vivo 
cervical tissue. Acad. Radiol., 9:504–12.
Crowell, K.J., Franzin, C.M., Koltay, A. et al. 2003. Expression and cha-
racterization of the FXYD ion transport regulators for NMR struc-
tural studies in lipid micelles and lipid bilayers. Biochim. Biophys. 
Acta., 1645(1):15–21.
Ceska, T.A., Owens, R., Doyle, C. et al. The crystal structure of the Fgfr2 
tyrosine kinase domain in complex with 4-aryl-2-phenylamino pyri-
midine angiogenesis inhibitors. To be Published.
Davis, T., Walker, J.R., Dong, A. et al. 2006. Structure of the human Epha3 
receptor tyrosine kinase and juxtamembrane region. To be 
Published.
Del Sal, G., Ruaro, M.E., Philipson, L. et al. 1992. The growth arrest-speciﬁ  c 
gene, gas1, is involved in growth suppression. Cell., 70(4):595–607.
Doorbar, J. 2006. Molecular biology of human papillomavirus infection and 
cervical cancer. Clin. Sci. (Lond)., 110:525–41.
Dower, S.K., Kronheim, S.R., Hopp, T.P. et al. 1986. The cell surface 
receptors for interleukin-1 alpha and interleukin-1 beta are identical. 
Nature, 324(6094):266–8.
Druker, B.J. 2004. Imatinib as a paradigm of targeted therapies. Adv.Cancer 
Res., 91:1–30.
Duffy, C.L., Phillips, S.L. and Klingelhutz, A.J. 2003. Microarray analysis 
identiﬁ  es differentiation-associated genes regulated by human papil-
lomavirus type 16 E6. Virology, 314:196–205.
Dufner-Beattie, J., Langmade, S.J., Wang, F. et al. 2003. Structure, function, 
and regulation of a subfamily of mouse zinc transporter genes. 
J. Biol. Chem., 278(50):50142–50.
Dukhovny, A., Goldstein Magal, L. and Hirschberg, K. 2006. The MAL 
proteolipid restricts detergent-mediated membrane pore expansion 
and percolation. Mol. Membr. Biol., 23(3):245–57.
Entrez Gene. 2007. URL: www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene
Entrez GEO URL: www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=geo
Ernst, L.K., van de Winkel, J.G., Chiu, I.M. et al. 1992. Three genes 
for the human high affinity Fc receptor for IgG (Fc gamma RI) 
encode four distinct transcription products. J. Biol. Chem., 
267(22):15692–700.
Evdokiou, A. and Cowled, P.A. 1998. Tumor-suppressive activity of the 
growth arrest-speciﬁ  c gene GAS1 in human tumor cell lines. Int. J. 
Cancer, 75(4):568–77.454
Kneller et al
Biomarker Insights 2007:2
Fedarovich, A., Tomberg, J., Nicholas, R.A. et al. 2006. Structure of the 
N-terminal domain of human CEACAM1: binding target of the 
opacity proteins during invasion of Neisseria meningitidis and 
N. gonorrhoeae. Acta. Crystallogr.,Sect.D, 62:971–9.
Ferris, D.G., Lawhead, R.A., Dickman, E.D. et al. 2001. Multimodal hyper-
spectral imaging for the noninvasive diagnosis of cervical neoplasia. 
J. Low.Genital. Tract. Dis., 5(2):65–72.
Flanagan, J.G., Vanderhaeghen, P. 1998. The ephrins and Eph receptors in 
neural development. Annu. Rev. Neurosci., 21:309–45. Review.
Florek, M., Haase, M., Marzesco, A.M. et al. 2005. Prominin-1/CD133, a 
neural and hematopoietic stem cell marker, is expressed in adult 
human differentiated cells and certain types of kidney cancer. Cell. 
Tissue Res., 319(1):15–26.
Franzin, C.M., Yu, J., Thai, K. et al. 2005. Correlation of gene and protein 
structures in the FXYD family proteins. J. Mol. Biol., 354(4):743–50.
Frater, J.L., Tallman, M.S., Variakojis, D. et al. 2003. Chronic myeloid 
leukemia following therapy with imatinib mesylate (Gleevec) Bone 
marrow histopathology and correlation with genetic status. American 
Journal of Clinical Pathology, 119(6):833–41.
Gaither, L.A. and Eide, D.J. 2000. Functional expression of the human 
hZIP2 zinc transporter. J. Biol. Chem., 275:5560–64.
Gaither, L.A. and Eide, D.J. 2001. The human ZIP1 transporter mediates 
zinc uptake in human K562 erythroleukemia cells. J. Biol. Chem., 
276:22258–64.
Garrett, TPJ., McKern, N.M., Lou, M. et al. 2002. Crystal structure of a 
truncated epidermal growth factor receptor extracellular domain 
bound to transforming growth factor alpha. Cell., 110:763–73.
Gillenwater, A., Jacob, R. and Richards-Kortum, R. 1998. Fluorescence 
spectroscopy: a technique with potential to improve the early detec-
tion of aerodigestive tract neoplasia. Head Neck, 20:556–62.
González, S., White, W.M., Rajadhyaksha, M. et al. 1999. Confocal imaging 
of sebaceous gland hyperplasia in vivo to assess efﬁ  cacy and mecha-
nism of pulsed dye laser treatment. Lasers in Surgery and Medicine, 
25:8–12.
Gurjar, R.S., Backman, V., Perelman, L.T. et al. 2001. Imaging human 
epithelial properties with polarized light-scattering spectroscopy. Nat. 
Med., 7(11):1245–8.
Hahn, M., Nicholson, M.J., Pyrdol, J. et al. 2005. Unconventional topology 
of self peptide-major histocompatibility complex binding by a human 
autoimmune T cell receptor. Nat. Immunol., 6:490–96.
Hamburger, A.E., West Jr, A.P. and Bjorkman, P.J. 2004. Crystal structure 
of a polymeric immunoglobulin binding fragment of the human 
polymeric immunoglobulin receptor. Structure, 12:1925–35.
Hanahan, D. and Weinburg, R.A. 2000. The hallmarks of cancer. Cell., 
100:57–70.
Hanakawa, Y., Selwood, T., Woo, D. et al. 2003. Calcium-dependent con-
formation of desmoglein 1 is required for its cleavage by exfoliative 
toxin. J. Invest. Dermatol., 121(2):383–9.
Hanke, S., Bugert, P., Chudek, J. et al. 2001. Cloning a calcium channel 
alpha2delta-3 subunit gene from a putative tumor suppressor gene 
region at chromosome 3p21.1 in conventional renal cell carcinoma. 
Gene., 264(1):69–75.
Hansen, L.V., Gardsvoll, H., Nielsen, B.S. et al. 2004. Structural analysis 
and tissue localization of human C4.4A: a protein homologue of the 
urokinase receptor. Biochem. J., 380(Pt 3):845–57.
Harada, N., Iijima, S., Kobayashi, K. et al. 1997. Human IgGFc binding 
protein (FcgammaBP) in colonic epithelial cells exhibits mucin-like 
structure. J. Biol. Chem., 272(24):15232–41.
Harisinghani, M.G., Barentsz, J., Hahn, P.F. et al. 2003. Non-invasive detec-
tion of clinically occult lymph-node metastases in prostate cancer. 
N. Engl. J. Med., 348:2491–99.
Harvey, T.S., Wilkinson, A.J., Tappin, M.J. et al. 1991. The solution struc-
ture of human transforming growth factor alpha. Eur. J. Biochem., 
198:555–62.
Herter, S., Piper, D.E., Aaron, W. et al. 2005. Hepatocyte growth factor is 
a preferred in vitro substrate for human hepsin, a membrane-anchored 
serine protease implicated in prostate and ovarian cancers. Bio-
chem. J., 390:125–36.
Horn, P.A., Tesch, H., Staib, P. et al. 1999. Expression of AC133, a novel 
hematopoietic precursor antigen, on acute myeloid leukemia cells. 
Blood, 93(4):1435–7.
Huang, M.E., Ye, Y.C., Chen, S.R. et al. 1988. Use of all-trans retinoic acid 
in the treatment of acute promyelocytic leukemia. Blood, 
72(2):567–72.
Hubbard, TJP., Aken, B.L., Beal, K. et al. 2006. Ensembl 2007. Nuc. Acids 
Res. 00:Database issue D1–D8.
Huzaira, M., Rius, F., Rajadhyaksha, M. et al. 2001. Topographic variations 
in normal skin, as viewed by in vivo reﬂ  ectance confocal microscopy. 
The Journal of Investigative Dermatology, 116:846–52.
Ihrie, R.A. and Attardi, L.D. 2004. Perp-etrating p53-dependent apoptosis. 
Cell. Cycle, 3(3):267–9.
Iida, A., Tanaka, T. and Nakamura, Y. 2003. High-density SNP map of human 
ITR, a gene associated with vascular remodeling. J. Hum. Genet., 
48(4):170–2.
Ishikawa, J., Kaisho, T., Tomizawa, H. et al. 1995. Molecular cloning and 
chromosomal mapping of a bone marrow stromal cell surface gene, 
BST2, that may be involved in pre-B-cell growth. Genomics, 
26(3):527–34.
Jaffer, F.A. and Weissleder, R. 2005. Molecular imaging in the clinical arena. 
JAMA., 293(7):855–62.
Jain, A., Tindell, C.A., Laux, I. et al. 2005. Proc. Natl. Acad. Sci. 
U.S.A., 102(33):11858–63.
Jasanoff, A., Wagner, G. and Wiley, D.C. 1998. Structure of a trimeric 
domain of the MHC class II-associated chaperonin and targeting 
protein Ii. EMBO. J., 17:6812–18.
Jeong, D.G., Kim, S.J., Kim, J.H. et al. 2005. Trimeric structure of PRL-1 
phosphatase reveals an active enzyme conformation and regulation 
mechanisms. J.Mol.Biol., 345:401–13.
Kalabis, J., Rosenberg, I. and Podolsky, D.K. 2006. Vangl1 protein acts as 
a downstream effector of intestinal trefoil factor (ITF)/TFF3 signaling 
and regulates wound healing of intestinal epithelium. J. Biol. Chem., 
281(10):6434–41.
Kharitonenkov, A., Chen, Z., Sures, I. et al. 1997. A family of proteins that 
inhibit signalling through tyrosine kinase receptors. Nature, 
386(6621):181–6.
Khoury, T., Chadha, K., Javle, M. et al. 2005. Expression of intestinal trefoil 
factor (TFF-3) in hepatocellular carcinoma. Int. J. Gastrointest 
Cancer, 35(3):171–7.
Kim, J.Y., Kim, S.M., Ko, J.H. et al. 2006. Interaction of pro-apoptotic 
protein HGTD-P with heat shock protein 90 is required for induction 
of mitochondrial apoptotic cascades. FEBS. Lett., 580(13):3270–5.
Kim, K.A., Song, J.S., Jee, J. et al. 2004. Structure of human PRL-3, the 
phosphatase associated with cancer metastasis. Febs Lett, 
565:181–7.
Kobayashi, K., Hamada, Y., Blaser, M.J. et al. 1991. The molecular conﬁ  -
guration and ultrastructural locations of an IgG Fc binding site in 
human colonic epithelium. J. Immunol., 146(1):68–74.
Langley, R.G., Rajadhyaksha, M., Dwyer, P.J. et al. 2001. Confocal scanning 
laser microscopy of benign and malignant melanocytic skin lesions 
in vivo. Journal of the American Academy of Dermatology, 
45:365–76.
Lee, D.C., Rose, T.M., Webb, N.R. et al. 1985. Cloning and sequence 
analysis of a cDNA for rat transforming growth factor-alpha. Nature, 
313(6002):489–91.
Lee, M.J., Kim, J.Y., Suk, K. et al. 2004. Identiﬁ  cation of the hypoxia-inducible 
factor 1 alpha-responsive HGTD-P gene as a mediator in the 
mitochondrial apoptotic pathway. Mol. Cell. Biol., 24(9):3918–27.
Lee, J.W., Lee, Y.S., Yoo, K.H. et al. 2006. LY-6K gene: a novel molecular 
marker for human breast cancer. Oncol. Rep., 16(6):1211–4.
Lemercinier, X., Muskett, F.W., Cheeseman, B. et al. 2001. High-resolution 
solution structure of human intestinal trefoil factor and functional 
insights from detailed structural comparisons with the other members 
of the trefoil family of mammalian cell motility factors. Biochemis-
try, 40:9552–59.
Leng, L., Metz, C.N., Fang, Y. et al. 2003. MIF signal transduction initiated 
by binding to CD74. J. Exp. Med., 197:1467–76.455
SAGE and novel CIN cell surface targets
Biomarker Insights 2007:2
Li, Y.F., Li, D.F., Zeng, Z.H. et al. 2006. Trimeric structure of the wild 
soluble chloride intracellular ion channel CLIC4 observed in crystals. 
Biochem. Biophys. Res. Commun., 343:1272–78.
Livnah, O., Stura, E.A., Johnson, D.L. et al. 1996. Functional mimicry of 
a protein hormone by a peptide agonist: the EPO receptor complex 
at 2.8 Å. Science, 273:464–71.
Llorente, A., de Marco, M.C. and Alonso, M.A. 2004. Caveolin-1 and MAL 
are located on prostasomes secreted by the prostate cancer PC-3 cell 
line. J. Cell. Sci., 117(Pt 22):5343–51.
LOCATE. subcellular localization database. Copyright 2004, 2005, Institute 
of Molecular Bioscience, University of Queensland and the ARC 
Centre in Bioinformatics.
Macao, B., Johansson, DGA., Hansson, G.C. et al. 2006. Autoproteolysis 
coupled to protein folding in the SEA domain of the membrane-bound 
MUC1 mucin. Nat. Struct. Mol. Biol., 13:71–6.
Machesky, L.M., Reeves, E., Wientjes, F. et al. 1997. Mammalian actin-
related protein 2/3 complex localizes to regions of lamellipodial 
protrusion and is composed of evolutionarily conserved proteins. 
Biochem. J., 328(Pt 1):105–12.
Madden, D.R., Gorga, J.C., Strominger, J.L. et al. 1992. The three-dimen-
sional structure of HLA-B27 at 2.1 Å resolution suggests a general 
mechanism for tight peptide binding to MHC. Cell, 70:1035–48.
Madden, S.L., Wang, C.J. and Landes, G. 2000. Serial analysis of gene 
expression: from gene discovery to target identiﬁ  cation. Drug Dis-
covery Today, 5(9):415–25.
Mao, M., Yu, M., Tong, J-H. et al. 1996. RIG-E, a human homolog of the 
murine Ly-6 family, is induced by retinoic acid during the differen-
tiation of acute promyelocytic leukemia cell. PNAS., 93:5910–14.
Marquardt, A., Stohr, H., White, K. et al. 2000. cDNA cloning, genomic 
structure, and chromosomal localization of three members of the 
human fatty acid desaturase family. Genomics, 66(2):175–83.
Matter, W.F., Estridge, T., Zhang, C. et al. 2001. Role of PRL-3, a human 
muscle-speciﬁ  c tyrosine phosphatase, in angiotensin-II signaling. 
Biochem. Biophys. Res. Commun., 283(5):1061–8.
McMahan, C.J., Slack, J.L., Mosley, B. et al. 1991. A novel IL-1 receptor, 
cloned from B cells by mammalian expression, is expressed in many 
cell types. EMBO. J., 10(10):2821–32.
Muller, D.J., Hand, G.M., Engel, A. et al. 2002. Conformational changes 
in surface structures of isolated connexin 26 gap junctions. EMBO. 
J., 21(14):3598–607.
Murthy, V.L. and Stern, L.J. 1997. The class II MHC protein HLA-DR1 in 
complex with an endogenous peptide: implications for the structural 
basis of the speciﬁ  city of peptide binding. Structure, 5:1385–96.
Muskett, F.W., May, F.E., Westley, B.R. et al. 2003. Solution structure of 
the disulﬁ  de-linked dimer of human intestinal trefoil factor (TFF3): 
the intermolecular orientation and interactions are markedly different 
from those of other dimeric trefoil proteins. Biochemistry, 
42(51):15139–47.
Nagashima, K., Hayashi, F., Yoshida, M. et al. 2005. Solution structure of 
the ﬁ  rst ig-like domain of signal-regulatory protein beta-1 (SIRP-
beta-1). To be Published.
Naujokas, M.F., Morin, M., Anderson, M.S. et al. 1993. The chondroitin 
sulfate form of invariant chain can enhance stimulation of T cell 
responses through interaction with CD44. Cell., 74:257–68.
Nishihira, J., Ishibashi, T., Fukushima, T. et al. 2003. Macrophage migration 
inhibitory factor (MIF): its potential role in tumor growth and tumor-
associated angiogenesis. Ann. NY. Acad. Sci., 995:171–82.
Nowakowski, J., Cronin, C.N., McRee, D.E. et al. 2003. Structures of the 
cancer related Aurora-A, FAK and EphA2 protein kinases from 
nanovolume crystallography. Structure, 10:1659–67.
O’Brien, T.J., Beard, J.B., Underwood, L.J. et al. 2001. The CA 125 gene: 
an extracellular superstructure dominated by repeat sequences. 
Tumour Biol., 22(6):348–66.
O’Donovan, N., Fischer, A., Abdo, E.M. et al. 2002. Differential expression 
of IgG Fc binding protein (FcgammaBP) in human normal thyroid 
tissue, thyroid adenomas and thyroid carcinomas. J. Endocrinol., 
174(3):517–24.
Okada, H., Kimura, M.T., Tan, D. et al. 2005. Frequent trefoil factor 3 
(TFF3) overexpression and promoter hypomethylation in mouse and 
human hepatocellular carcinomas. Int. J. Oncol., 26(2):369–77.
Palmiter, R.D. and Findley, S.D. 1995. Cloning and functional characteriza-
tion of a mammalian zinc transporter that confers resistance to zinc. 
EMBO. J., 14(4):639–49.
Papanicolaou, G.N. and Traut, H.F. 1943. Diagnosis of Uterine Cancer by 
the Vaginal Smear. New York: The Commonwealth Fund. 1997. The 
diagnostic value of vaginal smears in carcinoma of the uterus, 1941. 
1997. Arch. Pathol. Lab. Med., 121(3):211–24.
Pérez-Plasencia, C., Riggins, G., Vázquez-Ortiz, G. et al. 2005. Character-
ization of the global proﬁ  le of genes expressed in cervical epithelium 
by Serial Analysis of Gene Expression (SAGE). BMC Genomics, 
6:130–8.
Pleasance, E.D., Marra, M.A. and Jones, SJM. 2003. Assessment of SAGE 
in transcript identiﬁ  cation. Genome Res., 13:1203–15.
Pollan, M., Varela, G., Torres, A. et al. 2003. Clinical value of p53, c-erbB-2, 
CEA and CA125 regarding relapse, metastasis and death in resectable 
non-small cell lung cancer. Int. J. Cancer, 107(5):781–90.
Pruitt, K.D., Katz, K.S., Sicotte, H. et al. 2000. Introducing RefSeq and 
LocusLink: curated human genome resources at the NCBI. Trends 
Genet., 16(1):44–7.
Pruitt, K.D., Tatusova, T. and Maglott, D.R. 2005. NCBI Reference Sequence 
(RefSeq): a curated non-redundant sequence database of genomes, 
transcripts and proteins. Nucleic Acids Res., 33(1):D501–D504.
Rabassa, M.E., Croce, M.V., Pereyra, A. et al. 2006. MUC1 expression and 
anti-MUC1 serum immune response in head and neck squamous cell 
carcinoma (HNSCC): a multivariate analysis. BMC. Cancer, 
6:253.
Raina, D., Ahmad, R., Kumar, S. et al. 2006. MUC1 oncoprotein blocks 
nuclear targeting of c-Abl in the apoptotic response to DNA damage. 
EMBO. J., 25(16):3774–83.
Rahman, M., Abd-El-Barr, M., Mack, V. et al. 2005. Optical imaging of 
cervical pre-cancers with structured illumination: An integrated 
approach. Gynecologic Oncology, 99:S112–S115.
Rajadhyaksha, M., Anderson, R.R. and Webb, R.H. 1999. Video-rate con-
focal scanning laser microscope for imaging human tissues in vivo. 
Applied Optics, 38:2105–15.
Ramanujam, N. 2000. Fluorescence spectroscopy of neoplastic and non-
neoplastic tissues. Neoplasia, 2(1–2):89–117.
Reiter, R.E., Gu, Z., Watabe, T. et al. 1998. Prostate stem cell antigen: a cell 
surface marker overexpressed in prostate cancer. Proc. Natl. Acad. 
Sci. U.S.A., 95(4):1735–40.
Ren, J., Raina, D., Chen, W. et al. 2006. MUC1 oncoprotein functions in 
activation of ﬁ  broblast growth factor receptor signaling. Mol. Cancer 
Res., 4(11):873–83.
Riedel, I., Liang, F.X., Deng, F.M. et al. 2005. Urothelial umbrella cells of 
human ureter are heterogeneous with respect to their uroplakin 
composition: different degrees of urothelial maturity in ureter and 
bladder? Eur. J. Cell. Biol., 84(2–3):393–405.
Ripani, E., Sacchetti, A., Corda, D. et al. 1998. Human Trop-2 is a tumor-
associated calcium signal transducer. Int. J. Cancer, 76(5):671–6.
Ritzka, M., Stanke, F., Jansen, S. et al. 2004. The CLCA gene locus as a 
modulator of the gastrointestinal basic defect in cystic ﬁ  brosis. Hum. 
Genet., 115(6):483–91.
Rivat, C., Rodrigues, S., Bruyneel, E. et al. 2005. Implication of STAT3 
signaling in human colonic cancer cells during intestinal trefoil 
factor 3 (TFF3)—and vascular endothelial growth factor-mediated 
cellular invasion and tumor growth. Cancer Res., 65(1):195–202.
Robertson, N., Oveisi-Fordorei, M., Zuyderduyn, S. et al. 2007. Discove-
rySpace: an interactive data analysis application. Genome Biology, 
8:R6.
Robinson, R.C., Turbedsky, K., Kaiser, D.A. et al. 2001. Crystal structure 
of Arp2/3 complex. Science, 294:679–84.
Ross, J.S., Fletcher, J.A., Bloom, K.J. et al. 2004. Targeted therapy in breast 
cancer: the HER-2/neu gene and protein. Mol.Cell. Proteomics, 
3(4):379–98.456
Kneller et al
Biomarker Insights 2007:2
Rouleau, C., Roy, A., St Martin, T. et al. 2006. Protein tyrosine phosphatase 
PRL-3 in malignant cells and endothelial cells: expression and func-
tion. Mol. Cancer Ther., 5(2):219–29.
Rudin, M. and Weissleder, R. 2003. Molecular imaging in drug discovery 
and development. Nat. Rev. Drug Discov., 2:123–31.
Ruutu, M., Peitsaro, P., Johansson, B. et al. 2002. Transcriptional proﬁ  ling 
of a human papillomavirus 33-positive squamous epithelial cell line 
which acquired a selective growth advantage after viral integration. 
Int. J. Cancer, 100:318–26.
Saha, S., Sparks, A.B., Rago, C. et al. 2002. Using the transcriptome to 
annotate the genome. Nat. Biotechnol., 20:508–12.
Sander, J., Ng, R.T., Sleumer, M.C. et al. 2005. A methodology for analyz-
ing SAGE libraries for cancer proﬁ  ling. ACM Transactions on 
Information Systems, 23(1):35–60.
Schaeffer, L., Gohlke, H., Muller, M. et al. 2006. Common genetic variants 
of the FADS1 FADS2 gene cluster and their reconstructed haplotypes 
are associated with the fatty acid composition in phospholipids. Hum. 
Mol. Genet., 15(11):1745–56.
Schiemann, S., Ruckels, M., Engelholm, L.H. et al. 1997. Differential gene 
expression in human mammary carcinoma cells: identiﬁ  cation of a 
new member of a receptor family. Anticancer Res., 17(1A):13–20.
Schreuder, H., Tardif, C., Trump-Kallmeyer, S. et al. 1997. A new cytokine-
receptor binding mode revealed by the crystal structure of the IL-1 
receptor with an antagonist. Nature, 386:194–200.
Selkin, B., Rajadhyaksha, M., González, S. et al. 2001. In vivo confocal 
microscopy in dermatology. Dermatologic Clinics, 19(2):369–77.
Shadeo, A., Chari, R., Lonergan, K.M., Pusic, A., Miller, D., Ehlen, T., Van 
Niekerk, D., Matisic, J., Richards-Kortum, R., Follen, M., Guillaud, 
M., Lam, W.L. and MacAulay, C. 2007. BMC Genomics. Submitted 
September.
Shim, C., Zhang, W., Rhee, C.H. et al. 1998. Proﬁ  ling of differentially 
expressed genes in human primary cervical cancer by complementary 
DNA expression array. Clin. Cancer Res., 4:3045–50.
Sokolov, K., Drezek, R., Gossage, K. et al. 1999. Reﬂ  ectance spectroscopy 
with polarized light: is it sensitive to cellular and nuclear morphol-
ogy? Opt. Express, 5(13):302.
Sokolov, K., Follen, M. and Richards-Kortum, R. 2002. Optical spectroscopy 
for detection of neoplasia. Curr. Opin. Chem. Biol., 6:651–58.
Sokolov, K., Aaron, J., Hsu, B. et al. 2003. Optical systems for in vivo 
molecular imaging of cancer. Technology in Cancer Research and 
Treatment, 2(6):491–504.
Sondermann, P., Huber, R., Oosthuizen, V. et al. 2000. The 3.2-A crystal 
structure of the human IgG1 Fc fragment-Fc gammaRIII complex. 
Nature, 406:267–73.
Stern, N., Markel, G., Arnon, T.I. et al. 2005. Carcinoembryonic antigen 
(CEA) inhibits NK killing via interaction with CEA-related cell 
adhesion molecule 1. J. Immunol., 174(11):6692–701.
Stumptner-Cuvelette, P. and Benaroch, P. 2002. Multiple roles of the invari-
ant chain in MHC class II function. Biochim. Biophys. Acta., 
1542:1–13.
Subramanian, S., Parthasarathy, R., Sen, S. et al. 2006. Species- and cell 
type-speciﬁ  c interactions between CD47 and human SIRPalpha. 
Blood, 107(6):2548–56.
Sun, H.W., Bernhagen, J., Bucala, R. et al. 1996. Crystal structure at 2.6-Å 
resolution of human macrophage migration inhibitory factor. Proc.
Natl. Acad. Sci. U.S.A., 93:5191–96.
Thomas, J.T., Oh, S.T., Terhune, S.S. et al. 2001. Cellular changes induced 
by low-risk human papillomavirus type 11 in keratinocytes that 
stably maintain viral episomes. J. Virol., 75:7564–71.
Todd, S.C., Doctor, V.S. and Levy, S. 1998. Sequences and expression of 
six new members of the tetraspanin/TM4SF family. Biochim. Biophys. 
Acta., 1399(1):101–4.
Tsuji, H., Okamoto, K., Matsuzaka, Y. et al. 2003. SLURP-2, a novel mem-
ber of the human Ly-6 superfamily that is up-regulated in psoriasis 
vulgaris. Genomics, 81(1):26–33.
Utzinger, U., Brewer, M., Silva, E. et al. 2001. Reﬂ  ectance spectroscopy 
for in vivo characterization of ovarian tissue. Lasers Surg. Med., 
28:56–66.
Velculescu, V.E., Zhang, L., Zhou, W. et al. 1997. Characterization of the 
yeast transcriptome. Cell., 88(2):243–51.
Velculescu, V.E., Zhang, L., Vogelstein, B. et al. 1995. Serial analysis of 
gene expression. Science, 270:484–7.
Vieten, D., Corﬁ  eld, A., Carroll, D. et al. 2005. Impaired mucosal regen-
eration in neonatal necrotising enterocolitis. Pediatr. Surg. Int., 
21(3):153–60.
Wagnières, G.A., Star, W.M. and Wilson, B.C. 1998. In vivo ﬂ  uorescence 
spectroscopy and imaging for oncological applications. Photochem. 
Photobiol., 68(5):603–32.
Weissleder, R. 2002. Scaling down imaging: molecular mapping of cancer 
in mice. Nat. Rev. Cancer, 2:11–18.
Welch, M.D., Iwamatsu, A. and Mitchison, T.J. 1997. Actin polymerization 
is induced by Arp2/3 protein complex at the surface of Listeria 
monocytogenes. Nature, 385(6613):265–9.
Wente, M.N., Jain, A., Kono, E. et al. 2005. Prostate stem cell antigen is a 
putative target for immunotherapy in pancreatic cancer. Pancreas, 
31(2):119–25.
Wheeler, G.N., Parker, A.E., Thomas, C.L. et al. 1991. Desmosomal gly-
coprotein DGI, a component of intercellular desmosome junctions, 
is related to the cadherin family of cell adhesion molecules. Proc. 
Natl. Acad. Sci. U.S.A., 88(11):4796–800.
White, W.M., Rajadhyaksha, M., González, S. et al. 1999. Noninvasive 
imaging of human oral mucosa in vivo by confocal reﬂ  ectance 
microscopy. Laryngoscope, 109:1709–17.
Winkler, M.E., O’Connor, L., Winget, M. et al. 1989. Epidermal growth 
factor and transforming growth factor alpha bind differently to the 
epidermal growth factor receptor. Biochemistry, 28(15):6373–8.
Wollscheid, V., Kuhne-Heid, R., Stein, I. et al. 2002. Identiﬁ  cation of a new 
proliferation-associated protein NET-1/C4.8 characteristic for a 
subset of high-grade cervical intraepithelial neoplasia and cervical 
carcinomas. Int. J. Cancer, 99(6):771–5.
Woodman, CBJ., Collins, S.I. and Young, L.S. 2007. The natural history of 
cervical HPV infection: unresolved issues. Nature Rev. Cancer, 
7:11–22.
Wu, A., Wiesner, S., Xiao, J. et al. 2006. Expression of MHC I and NK 
ligands on human CD133(+) glioma cells: possible targets of immu-
notherapy. J. Neurooncol. [Epub ahead of print].
Yasunaga, S., Grati, M., Cohen-Salmon, M. et al. 1999. A mutation in OTOF, 
encoding otoferlin, a FER-1-like protein, causes DFNB9, a nonsyn-
dromic form of deafness. Nat. Genet., 21(4):363–9.
Yeager, C.L., Ashmun, R.A., Williams, R.K. et al. 1992. Human aminopep-
tidase N is a receptor for human coronavirus 229E. Nature, 
357(6377):420–2.
Yee, K.W. and Keating, A. 2003. Advances in targeted therapy for chronic 
myeloid leukemia. Expert Review of Anticancer Therapy, 
3:295–310.
Yim, E.-K. and Park, J-S. 2006. Biomarkers in cervical cancer. Biomarker 
Insights, 2:215–25.
Yin, B.W., Dnistrian, A. and Lloyd, K.O. 2002. Ovarian cancer antigen 
CA125 is encoded by the MUC16 mucin gene. Int. J. Cancer, 
98(5):737–40.
Yu, J., Lin, J.H., Wu, X.R. et al. 1994. Uroplakins Ia and Ib, two major 
differentiation products of bladder epithelium, belong to a family of 
four transmembrane domain (4TM) proteins. J. Cell. Biol., 
125(1):171–82.
Zidi-Yahiaoui, N., Mouro-Chanteloup, I., D’Ambrosio, A.M. et al. 2005. 
Human Rhesus B and Rhesus C glycoproteins: properties of facilitated 
ammonium transport in recombinant kidney cells. Biochem. J., 
391(Pt 1):33–40.
zur Hausen, H. 2002. Papillomaviruses and cancer: from basic studies to 
clinical application. Nature Rev. Cancer, 2:342–50.457
SAGE and novel CIN cell surface targets
Biomarker Insights 2007:2
Appendix
Biomarker descriptions
ACTR3 ARP3 actin-related protein 3 homolog 
(yeast). The protein encoded by this gene is known 
to be a major constituent of the ARP2/3 complex 
(Welch et al. 1997). This complex is located at the 
cell surface and is essential to cell shape and motil-
ity through lamellipodial actin assembly and pro-
trusion (Machesky et al. 1997).
Structure information: 1K8K Crystal Structure 
of Arp2/3 Complex (Robinson et al. 2001).
ANPEP alanyl (membrane) aminopeptidase 
(aminopeptidase N, aminopeptidase M, micro-
somal aminopeptidase, CD13, p150). Human 
aminopeptidase N is a receptor for one strain of 
human coronavirus (Yeager et al. 1992; Breslin 
et al. 2003). The large extra-cellular carboxyter-
minal domain contains a pentapeptide consensus 
sequence characteristic of members of the zinc-
binding metalloproteinase super-family. Defects 
in this gene appear to be a cause of various types 
of leukemia or lymphoma.
BST2 bone marrow stromal cell antigen 2. Bone 
marrow stromal cells are involved in the growth and 
development of B-cells and this protein may play a 
role in pre-B-cell growth (Ishikawa et al. 1995).
C3orf28 chromosome 3 open reading frame 28 
(HGTD-P). When overexpressed, HGTD-P induces 
cell death via mitochondrial apoptotic cascades 
(Lee et al. 2004; Kim et al. 2006).
C14orf101 chromosome 14 open reading frame 
101. Integral to membrane (Ensembl-Gene 
ENSG00000070269: inferred from electronic 
annotation).
CACNA2D3 calcium channel, voltage-depen-
dent, alpha 2/delta 3 subunit. This gene encodes a 
member of the alpha-2/delta subunit family, a 
protein in the voltage-dependent calcium channel 
complex (Hanke et al. 2001).
CD74 CD74 molecule, major histocompatibil-
ity complex MHC, class II invariant chain. CD74 
is a nonpolymorphic type II integral membrane 
protein with an N-terminal cytoplasmic tail. CD74 
is a regulated intra-membrane proteolysis RIP 
protein and its roles as a chaperone and as a signal-
ling molecule are tightly regulated (Stumptner-
Cuvelette and Benaroch, 2002; Becker-Herman 
et al. 2005). In addition, CD74 is an accessory 
signalling molecule during T-cell responses 
through interactions with CD44 (Naujokas et al. 
1993). Providing further evidence for its role in 
signal transduction pathways, CD74 is now known 
to be a high afﬁ  nity binding protein for the proin-
flammatory cytokine, macrophage migration-
inhibitory factor (MIF); MIF binds to the 
extracellular domain of CD74 (Leng et al. 2003). 
MIF is also implicated in tumour cell growth and 
angiogenesis (Nishihira, et al. 2003).
Structure information: 1IIE (75 amino acids; 
296 in CD74) HLA-DR antigens associated invari-
ant chain (Jasanoff et al. 1998). 1MIF Macrophase 
migration inhibitory factor (MIF) (Sun et al. 
1996).
CEACAM5 carcinoembryonic antigen-related 
cell adhesion molecule 5. CEACAM1 interacts 
heterophilically with the CEA (CEACAM5) pro-
tein. Because CEA is expressed on a wide range 
of carcinomas and commonly used as tumour 
marker, a novel role for the CEA protein enabling 
the escape of tumour cells from NK-mediated kill-
ing is now apparent (Stern et al. 2005).
Structure information: 1E07 Model of human 
carcinoembryonic antigen by homology modelling 
and curve-ﬁ  tting to experimental solution scatter-
ing data (Boehm and Perkins, 2000). 2GK2 Crys-
tal structure of the N-terminal domain of human 
CEACAM1 (Fedarovich et al. 2006). Using the 
BLOSUM62 comparison matrix, CEACAM1 (468 
residues) has 74.3% identity to CEACAM5 (702 
residues) in 412 residue overlap.
CLCA4 chloride channel, calcium activated, 
family member 4. The protein encoded by this gene 
belongs to the calcium sensitive chloride conduc-
tance protein family; the exact function is not 
known (Agnel et al. 1999; Ritzka et al. 2004).
CLIC6 chloride intracellular channel 6. This 
gene encodes a member of the chloride intracel-
lular channel family of proteins.
Structure information: 2D2Z Crystal structure 
of soluble form of CLIC4 (Li et al. 2006).
DSG1 desmoglein 1. Desmoglein 1 is a calcium-
binding trans-membrane glycoprotein component 
of desmosomes in vertebrate epithelial cells 
(Wheeler et al. 1991; Hanakawa et al. 2003).
EMP1 epithelial membrane protein 1. A well-
known tumour-associated gene and a member of 
a novel family of genes encoding membrane gly-
coproteins (Ben-Porath and Benvenisty, 1996; 
Schiemann et al. 1997), EMP1 is a biomarker of 
geﬁ  tinib resistance (Jain et al. 2005). Geﬁ  tinib is 
a small-molecule inhibitor that competes for the 
ATP-binding site on EGF receptor (EGFR) and has 458
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been approved for patients with advanced lung 
cancers.
Structure information: 1EBP Complex between 
the extracellular domain of erythropoietin (EPO) 
receptor [EBP] and an agonist peptide [EMP1] 
(Livnah et al. 1996).
EPHA1 EPH receptor A1. EPH and EPH-related 
receptors have been implicated in mediating devel-
opmental events, particularly in the nervous system 
(Flanagan and Vanderhaeghen, 1998). Structure 
information: 2GSF The Human Epha3 Receptor 
Tyrosine Kinase and Juxtamembrane Region 
(Davis et al. 2006). 1MQB Crystal Structure of 
Ephrin A2 (ephA2) Receptor Protein Kinase 
(Nowakowski et al. 2003).
FADS2 fatty acid desaturase 2. FADS family 
members are considered fusion products composed 
of an N-terminal cytochrome b5-like domain and 
a C-terminal multiple membrane-spanning desatu-
rase portion, both of which are characterized by 
conserved histidine motifs (Marquardt et al. 2000; 
Schaeffer et al. 2006).
FCGBP Fc fragment of IgG binding protein 
(Kobayashi et al. 1991; Harada et al. 1997; 
O’Donovan et al. 2002). The encoded protein is 
made up of 3004 amino acid residues.
FER1L4 fer-1-like 4 (C. elegans). Novel human 
gene OTOF is the second member of a mammalian 
gene family related to C. elegans fer-1. It encodes 
a predicted cytosolic protein with a single carboxy-
terminal trans-membrane domain. The sequence 
homologies and predicted structure of otoferlin, 
the protein encoded by OTOF, suggest its involve-
ment in vesicle membrane fusion (Yasunaga et al. 
1999).
FGFR2 fibroblast growth factor receptor 2 
(bacteria-expressed kinase, keratinocyte growth 
factor receptor, craniofacial dysostosis 1, Crouzon 
syndrome, Pfeiffer syndrome, Jackson-Weiss syn-
drome). FGFR2 is a high-afﬁ  nity receptor for 
acidic, basic and/or keratinocyte growth factor, 
depending on the isoform (Bansal et al. 1997). The 
extra-cellular portion of the protein interacts with 
ﬁ  broblast growth factors, setting in motion a cas-
cade of downstream signals, ultimately inﬂ  uencing 
mitogenesis and differentiation.
Structure information: 1OEC FGFR2 kinase 
domain (Ceska et al. 2004).
FLJ32028 transmembrane protein 154. Hypo-
thetical protein LOC201799. Integral to membrane 
(Ensembl-Gene ENSG00000170006: inferred 
from electronic annotation).
FXYD3 FXYD domain containing ion transport 
regulator 3. FXYD2, also known as the gamma 
subunit of the Na,K-ATPase, regulates the proper-
ties of that enzyme. Trans-membrane topology has 
been established for two family members (FXYD1 
and FXYD2), with the N-terminus extracellular 
and the C-terminus on the cytoplasmic side of the 
membrane (Crowell et al. 2003; Franzin et al. 
2005). The protein encoded by this gene may func-
tion as a chloride channel or as a chloride channel 
regulator.
GAS1 growth arrest-speciﬁ  c 1. GAS1 plays a 
role in growth suppression and blocks entry to S 
phase and prevents cycling of normal and trans-
formed cells (Del Sal et al. 1992). Gas1 is a puta-
tive tumour suppressor gene (Evdokiou and 
Cowled, 1998).
GJB2 gap junction protein, beta 2, 26kDa. The 
cytoplasmic domains of the connexion 26 gap 
junction surface, imaged at sub-molecular resolu-
tion, form a hexameric pore protruding from the 
membrane bilayer (Muller et al. 2002).
GPC4 glypican 4. Cell surface heparan sulfate 
proteoglycans are composed of a membrane-asso-
ciated protein core substituted with a variable 
number of heparan sulfate chains. These proteins 
may play a role in the control of cell division and 
growth regulation (Bernﬁ  eld et al. 1999).
HLA-B major histocompatibility complex, class 
I, B. HLA-B belongs to the HLA class I heavy 
chain paralogues. Class I molecules play a central 
role in the immune system by presenting peptides 
derived from the endoplasmic reticulum lumen and 
are expressed in nearly all cells. The heavy chain 
is anchored in the membrane.
Structure information: 1HSA The three-dimen-
sional structure of HLA-B27 at 2.1 Å resolution 
suggests a general mechanism for tight peptide 
binding to MHC (Madden et al. 1992).
HLA-DRA major histocompatibility complex, 
class II, DR alpha. It is a heterodimer consisting 
of an alpha and a beta chain, both anchored in the 
membrane, and it plays a central role in the immune 
system.
Structure information: 1AQD HLA-DR1 (DRA, 
DRB1 0101) Human class II histocompatibility 
protein (extracellular domain) complexed with 
endogenous (Murthy and Stern, 1997). 1YMM 
TCR/HLA-DR2b/MBP-peptide complex (Hahn 
et al. 2005).
IL1R1 interleukin 1 receptor, type I. This protein 
is a receptor for interleukin alpha, interleukin beta, 459
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and interleukin 1 receptor, type I (Dower et al. 
1986; McMahan et al. 1991). It is an important 
mediator involved in many cytokine induced 
immune and inﬂ  ammatory responses (Boch et al. 
2003). Structure information: 1IRA Complex of the 
interleukin-1 receptor with the interleukin-1 recep-
tor antagonist (IL1RA) (Schreuder et al. 1997).
ITR G protein-coupled receptor 180. This pro-
tein is produced predominantly in vascular smooth 
muscle cells and may play an important role in the 
regulation of vascular remodelling (Iida et al. 
2003).
LOC644410 FCGR1C Fc fragment of IgG, high 
afﬁ  nity Ic, receptor (CD64). Only Fc gamma RI has 
high afﬁ  nity for ligand and has a unique third extra-
cellular domain (EC3). Three genes for human Fc 
gamma RI (A, B, and C) have been characterised; 
although they are remarkably similar, genes B and 
C are notably different from A (Ernst et al. 1992).
Structure information: 1E4J Crystal structure of 
the soluble human FC-gamma receptor III 
(Sondermann et al. 2000).
LY6E lymphocyte antigen 6 complex, locus E. 
Acute promyelocytic leukemia APL is a human 
malignancy that responds to differentiation therapy 
with all-trans-retinoic acid ATRA (Huang et al. 
1988). ATRA induces the expression of a novel 
human gene, RIG-E (Mao et al. 1996). The amino 
acid composition of its product indicates that it is 
membrane-associated and has high homology to 
the murine LY-6 proteins and weak homology with 
a number of human growth factor receptors.
MGC45438 hypothetical protein MGC45438. 
Type I membrane protein (LOCATE).
LYNX1 Ly6/neurotoxin 1. Ly-6/neurotoxin gene 
family members are lymphocyte antigens that 
attach to the cell surface by a glycosylphosphati-
dylinositol anchor and have a unique structure 
displayed 8–10 conserved cysteine residues (Tsuji 
et al. 2003). Functional analysis indicates that 
LYNX1 can enhance nicotinic acetylcholine recep-
tor function in the presence of acetylcholine 
(Arredondo et al. 2006). It is a new marker for 
human breast cancer (Lee et al. 2006).
LYPD3 LY6/PLAUR domain containing 3 
(C4.4A). This protein is known to be a structural 
homologue of the urokinase-type plasminogen 
activator receptor (uPAR) but little is known about 
its function (Hansen et al. 2004).
MAL mal, T-cell differentiation protein. The 
protein encoded by this gene is a highly hydropho-
bic integral membrane protein belonging to the 
MAL family of proteolipids (Llorente et al. 2004; 
Dukhovny et al. 2006).
MUC1 mucin 1, cell-surface associated. This 
gene is a member of the mucin family and encodes 
a membrane bound, glycosylated phosphoprotein. 
The protein is anchored to the apical surface of 
many epithelia by a trans-membrane domain, with 
the degree of glycosylation varying with cell type. 
The protein serves a protective function by binding 
to pathogens and also functions in a cell signalling 
capacity (Ren et al. 2006). Over-expression, aber-
rant intracellular localization, and changes in 
glycosylation of this protein have been associated 
with carcinomas (Rabassa et al. 2006; Raina et al. 
2006).
Structure information: 2ACM Solution structure 
of the SEA domain of human mucin 1 (MUC1) 
(Macao et al. 2006).
MUC16 mucin 16 (CA125), cell surface associ-
ated. CA125 protein core is composed of a short 
cytoplasmic tail, a trans-membrane domain, and 
an extraordinarily large glycosylated extracellular 
structure. The extracellular domain encompasses 
an interactive disulﬁ  de bridged cysteine-loop and 
the site of OC125 and M11 binding (O’Brien et al. 
2001). It is known to be a marker in several cancers, 
including ovarian (Yin et al. 2002), renal (Bamias 
et al. 2003), and lung (Pollan et al. 2003).
NIP hypothetical protein FLJ32334 (DUOXA1). 
Multi-pass membrane protein (Ensembl-Gene 
ENSG00000140254: inferred from electronic 
annotation).
ODZ2 odz, odd Oz/ten-m homolog 2 (Dro-
sophila). This protein is membrane-bound tran-
scription regulator (Baqutti et al. 2003).
PERP PERP, TP53 apoptosis effector. This 
tetraspan protein localizes to the plasma mem-
brane, rather than to mitochondria, and may 
stimulate apoptosis (Ihrie and Attardi, 2004).
PIGR polymeric immunoglobulin receptor. 
PIGR mediates trans-cellular transport of poly-
meric immunoglobulin molecules. The receptor 
has 5 units with homology to the variable (V) units 
of immunoglobulins and a trans-membrane region, 
which also has some homology to certain immu-
noglobulin variable regions.
Structure information: 1XED Crystal Structure 
of a Ligand-Binding Domain of the Human Poly-
meric Ig Receptor, pIgR (Hamburger et al. 
2004).
PROM1 prominin 1. The PROM1 gene codes 
for a pentaspan trans-membrane glycoprotein. The 460
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PROM1 antigen appears to belong to a new 
molecular family of 5-TM proteins which include 
an extra-cellular N-terminus, two short intracellular 
loops, two large extra-cellular loops and an intra-
cellular C-terminus. PROM1 has been shown to 
be expressed on haemangioblasts and neural stem 
cells as well as on developing epithelium (Horn 
et al. 1999; Florek et al. 2005). No natural ligand 
has yet been demonstrated for the PROM1 mole-
cule (Wu et al. 2006).
PSCA prostate stem cell antigen. This gene 
encodes a glycosylphosphatidylinositol-anchored 
cell membrane glycoprotein and a target for 
immunotherapy (Reiter et al. 1998; Wente et al. 
2005 ).
PTP4A2 protein tyrosine phosphatase type IVA, 
member 2. The protein encoded by this gene 
belongs to a small class of prenylated protein tyro-
sine phosphatases (PTPs). PTPs are cell signalling 
molecules that play regulatory roles in a variety of 
cellular processes (Bardelli et al. 2003; Rouleau 
et al. 2006). Overexpression of this gene in mam-
malian cells conferred a transformed phenotype, 
which suggested its role in tumourigenesis (Cates 
et al. 1996).
Structure information: 1XM2 Crystal structure 
of Human PRL-1 (Jeong et al. 2005).
PTP4A3 protein tyrosine phosphatase type IVA, 
member 3. Over-expression of this PTP gene in 
mammalian cells was reported to inhibit angioten-
sin-II induced cell calcium mobilization and pro-
mote cell growth (Matter et al. 2001).
Structure information: 1V3A Structure of human 
PRL-3, the phosphatase associated with cancer 
metastasis (Kim et al. 2004).
PTPNS1 SIRPA signal-regulatory protein alpha. 
Signal-regulatory-protein (SIRP) family members 
are receptor-type transmembrane glycoproteins 
known to be involved in the negative regulation of 
receptor tyrosine kinase-coupled signalling pro-
cesses (Kharitonenkov et al. 1997). CD47 has been 
known to be a ligand for this PTPNS1 (Subramanian 
et al. 2006).
Structure information: 2D9C Solution structure 
of the ﬁ  rst ig-like domain of signal-regulatory 
protein beta-1 (SIRP-beta-1) (Nagashima et al. 
2005).
RHCG Rh family, C glycoprotein. RhCG 
facilitates ammonium movement across the plasma 
membrane (Zidi-Yahiaoui et al. 2005).
SLC30A1 solute carrier family 30 (zinc trans-
porter), member 1. Transports zinc out of cells; its 
absence accounts for increased sensitivity of mutant 
cells to zinc toxicity (Palmiter and Findley, 1995).
SLC39A3 solute carrier family 39 (zinc trans-
porter), member 3. These eight-transmembrane 
domain proteins are part of the Zrt/Irt-like protein 
(ZIP) super-family of metal ion transporters and 
contain a conserved 12-amino acid signature 
sequence within the fourth trans-membrane domain 
(Gaither and Eide, 2000, 2001; Dufner-Beattie 
et al. 2003).
SRD5A2L steroid 5 alpha-reductase 2-like; 3-
oxo-5-alpha-steroid 4 dehydrogen-ase activity.
STRA6 stimulated by retinoic acid gene 6 homo-
log (mouse). Stra6 codes for a very hydrophobic 
membrane protein of a new type, which does not 
display similarities with previously characterized 
integral membrane proteins (Bouillet et al. 
1997).
TACSTD2 tumour-associated calcium signal 
transducer 2. This gene encodes a carcinoma-
associated antigen, deﬁ  ned by the monoclonal 
antibody GA733. TACSTD2 transduces an intra-
cellular calcium signal and acts as a cell surface 
receptor (Ripani et al. 1998).
TFF3 trefoil factor 3. Trefoil family members 
are stable, secretory proteins having at least one 
copy of the trefoil motif, a 40-amino acid domain 
that contains three conserved disulphides. VANGL, 
Van Gogh-like protein 1, is phosphorylated in 
response to Intestinal Trefoil Factor (ITF) stimula-
tion. Vangl1 protein acts as a downstream effector 
of ITF/TFF3 signalling and regulates wound heal-
ing of the intestinal epithelium (Kalabis et al. 
2006). TFF3 is commonly expressed in hepatocel-
lular carcinoma and its expression correlates with 
tumour grade (Khoury et al. 2005).
Structure information: 1E9T High resolution 
solution structure of human intestinal trefoil factor 
(Lemercinier et al. 2001; Muskett et al. 2003).
TGFA transforming growth factor, alpha. TGF-
alpha shows about 40% sequence homology with 
epidermal growth factor (EGF) and competes with 
EGF for binding to the EGF receptor (Lee et al. 
1985; Winkler et al. 1989).
Structure information: 1MOX Crystal Structure 
of Human Epidermal Growth Factor Receptor 
(residues 1-501) in complex with TGF-alpha 
(Garret et al. 2002). 2TGF The solution structure of 
human transforming growth factor alpha (Harvey 
et al. 2001).
TMEM45B transmembrane protein 45B. 
Integral to membrane (Ensembl-Gene 461
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ENSG0000051715: inferred from electronic anno-
tation).
TMEM54 transmembrane protein 54. Integral 
to membrane (Ensembl-Gene ENSG00000121900: 
inferred from electronic annotation).
TMPRSS2 transmembrane protease, serine 2. 
This gene was demonstrated to be up-regulated by 
androgenic hormones in prostate cancer cells and 
down-regulated in androgen-independent prostate 
cancer tissue (Afar et al. 2001). The protease 
domain of this protein is thought to be cleaved and 
secreted into cell media after autocleavage.
The encoded protein contains a type II trans-
membrane domain, a receptor class A domain, a 
scavenger receptor cysteine-rich domain and a 
protease domain.
Structure information: 1Z8G Crystal structure 
of the extracellular region of the transmembrane 
serine protease hepsin with covalently bound pre-
ferred substrate (Herter et al. 2005).
TMPRSS11B transmembrane protease, serine 
11B. Integral to membrane (Ensembl-Gene 
ENSG00000185873: inferred from electronic 
annotation).
Structure information: 1Z8G (see TMPRSS2)
TSPAN1 tetraspanin 1. Most members of the 
trans-membrane 4 superfamily are cell-surface 
proteins characterized by the presence of four 
hydrophobic domains. The proteins mediate signal 
transduction events that play a role in the regulation 
of cell development, activation, growth and motil-
ity (Todd et al. 1998). Tetraspanin protein, C4.8, 
identical to NET-1, has been implicated in cervical 
carcinogenesis (Wollscheid et al. 2002).
UPK1A uroplakin 1A. The tetraspanin protein 
encoded by this gene is found in the asymmetrical 
unit membrane (AUM) where it can complex with 
other trans-membrane 4 superfamily proteins (Yu 
et al. 1994). It may play a role in regulating mem-
brane permeability of superﬁ  cial umbrella cells or 
in stabilizing the apical membrane through AUM/
cytoskeletal interactions (Riedel et al. 2005).